Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to
determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor
activity of ACY-241 for oral administration as monotherapy and in combination therapy with
orally administered pomalidomide and low-dose dexamethasone in eligible patients with
relapsed or relapsed-and-refractory multiple myeloma (MM).